



MODULE 6

CONTINUUM OF CARE

Coordinator Corner has developed this summary to assist your learning and help you fully understand the information featured in this video

Video breakdown by topic

1 Topic: The importance of continuation of care | Time: 0:12

- Each subsequent dose of SYNAGIS® (palivizumab) is as important as the first. That's why it's essential to do everything you can to ensure continuation of care through the full dosing schedule
 - It's important to continuously emphasize the need for adherence to monthly dosing
- Stewart et al study demonstrates the impact of noncompliance with dosing for SYNAGIS¹
 - In this retrospective analysis of 5,003 commercially insured infants¹:
 - 62% of eligible infants were noncompliant with SYNAGIS
 - Noncompliant infants: 5.9% RSV-related hospitalization rate
 - Compliant infants: 2.3% RSV-related hospitalization rate
 - Subjects were deemed compliant if they received ≥ 5 palivizumab doses without gaps (>35 days) during the RSV season and their first dose was received by November 30¹
 - Subjects were deemed noncompliant if they received <5 doses during RSV season¹
 - Conclusion: Infants who did not receive all monthly doses for SYNAGIS were 2 times more likely to be hospitalized for RSV-related illnesses than infants who received all doses on time¹

2 Topic: Ensure adherence: Keep track of visits | Time: 1:36

- You can help ensure patients adhere to therapy for SYNAGIS:
 - Keep track of scheduled visits and follow up with parents
 - Coordinator quick tip: View dates of additional doses in each patient's ID log. At every appointment, reinforce to parents the urgency to dose every 28 to 30 days throughout the RSV season

INDICATION & IMPORTANT SAFETY INFORMATION

SYNAGIS is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

- with a history of premature birth (≤ 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
- with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
- with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

SYNAGIS is contraindicated in children who have had a previous significant hypersensitivity reaction to SYNAGIS

Please see additional Important Safety Information on page 4, and accompanying full Prescribing Information for SYNAGIS, including Patient Information.

**3 Topic: Ensure adherence: Recommend Cradle with CareSM | Time: 2:23**

- Cradle with Care communicates directly with parents/caregivers to support your goal of 100% adherence to therapy
 - Parents who enroll in Cradle with Care receive a welcome email or letter as well as a helpful Welcome Kit, which includes:
 - An information booklet on RSV, SYNAGIS[®] (palivizumab), and Cradle with Care
 - Hand sanitizer
 - Stroller tag (reminds people to wash their hands before touching the baby)
 - Special calendar (keeps track of important dates and milestones)
 - Access 360 direct mail or email covering their affordability options
- Parents receive important reminders and communications via text,* email, or mail
 - RSV Season Start Reminder
 - Sent prior to start of RSV season to those who enrolled during RSV preseason
 - Appointment Reminders for SYNAGIS
 - Synced up with patient’s dosing plan and the area’s RSV season
 - End of RSV Season Reminders
 - Delivered via email or mail to congratulate parents/caregivers for helping their baby complete a season of therapy for SYNAGIS
 - Potential Second RSV Season Candidate Communication
 - Delivered to raise awareness that certain patients could still be at high risk in the next season
- Help them enroll in Cradle with Care: Parents should know that they have the option to enroll on their own—either online at CradleWithCare.com or using the business reply card in the patient brochure
 - Transition of Care (TOC) Form: Usually filled out prior to a baby’s discharge from the hospital
 - When you receive the TOC form from the hospital:
 - Check to see if the parent already opted in to either or both of the support programs
 - If they have, make a note of it in the patient ID log
 - Patient Authorization Form (PAF): Use if parents haven’t opted in to the programs
 - Allows MedImmune to help with any access issues that may arise
 - Available in print and electronic forms
 - Completing the online PAF at synagisPAF.com can help avoid issues of missing information or illegible handwriting

*Understand that the Cradle with Care program can send text messages if you provide your mobile phone number, and that text messaging rates apply.



cradle with care[™]

All Cradle with Care enrollment materials and communications are available in English and Spanish.

Please see Important Safety Information on page 4, and accompanying full Prescribing Information for SYNAGIS, including Patient Information.




4 Topic: Ensuring adherence: Monitor insurance changes | Time: 8:26

- Changes in insurance may mean that a patient's coverage does not automatically carry over to the next period
- You may be asked to submit an RSV virology report to demonstrate the prevalence of high RSV activity and support additional doses for a patient
- This report can help determine the optimal duration of SYNAGIS® (palivizumab) dosing based on the duration of the RSV season in that patient's area
- Find virology information at RSVAlert.com, a MedImmune-sponsored RSV surveillance program that uses laboratory data to monitor RSV activity to determine the start and end of RSV season.
 - Obtain a virology report at RSVAlert.com in the Resources section of this module, or ask your MedImmune representative for help
- Additional sources of local virology information include:
 - The CDC Surveillance Program
 - State health departments
 - Local hospitals

5 Topic: Ensuring adherence: Stay in ongoing contact with Specialty Pharmacy Provider (SPP) | Time: 9:35

- Help ensure adherence by staying in contact with the SPP to confirm that SYNAGIS doses are being delivered.
 - While this is out of a patient's hands, timely adherence starts with timely delivery of each dose
 - Coordinator Quick Tip: January is when many patients undergo insurance changes, so proactively advise parents in December to look out for those changes
- Access360™ can provide monthly reverification of benefits for eligible patients
 - If insurance has changed, you'll need to send the new insurance information to the SPP or to Access 360, when applicable, to verify if the patient is still covered
 - Note: If insurance changes, the SPP may change as well



If you want to become an official certified SYNAGIS coordinator, Coordinator Corner will help you every step of the way. All you have to do is view all the modules and take all the checkpoints to become certified and eligible to receive an educational textbook, or you can make a charitable donation.

You must be registered to be eligible for certification—**so register today.**

IMPORTANT SAFETY INFORMATION

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see additional Important Safety Information on page 4, and accompanying full Prescribing Information for SYNAGIS, including Patient Information.

IMPORTANT SAFETY INFORMATION

- SYNAGIS is contraindicated in children who have had a previous significant hypersensitivity reaction to SYNAGIS
- Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to SYNAGIS. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to SYNAGIS. The relationship between these reactions and the development of antibodies to SYNAGIS is unknown. If a significant hypersensitivity reaction occurs with SYNAGIS, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of SYNAGIS
- As with any intramuscular injection, SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder
- Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays
- Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported

INDICATION

SYNAGIS is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

- with a history of premature birth (≤ 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
- with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
- with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

DOSING

The recommended dose of SYNAGIS is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of SYNAGIS should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of SYNAGIS at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Please see accompanying full Prescribing Information for SYNAGIS, including Patient Information.

